1 Market Overview

• 1.1 Product Overview and Scope of Cancer Companion Diagnostic
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Classification of Cancer Companion Diagnostic by Type
  • 1.3.1 Overview: Global Cancer Companion Diagnostic Market Size by Type: 2018 Versus 2022 Versus 2029
  • 1.3.2 Global Cancer Companion Diagnostic Consumption Value Market Share by Type in 2022
  • 1.3.3 Polymerase Chain Reaction (PCR)
  • 1.3.4 “Next Generation” Sequencing (NGS)
  • 1.3.5 Fluorescence In Situ Hybridization (FISH)
  • 1.3.6 Immunohistochemistry (IHC)
• 1.4 Global Cancer Companion Diagnostic Market by Application
  • 1.4.1 Overview: Global Cancer Companion Diagnostic Market Size by Application: 2018 Versus 2022 Versus 2029
  • 1.4.2 Lung Cancer
  • 1.4.3 Colorectal Cancer
  • 1.4.4 Breast Cancer
  • 1.4.5 Others
• 1.5 Global Cancer Companion Diagnostic Market Size & Forecast
• 1.6 Global Cancer Companion Diagnostic Market Size and Forecast by Region
  • 1.6.1 Global Cancer Companion Diagnostic Market Size by Region: 2018 VS 2022 VS 2029
  • 1.6.2 Global Cancer Companion Diagnostic Market Size by Region, (2018-2029)
  • 1.6.3 North America Cancer Companion Diagnostic Market Size and Prospect (2018-2029)
  • 1.6.4 Europe Cancer Companion Diagnostic Market Size and Prospect (2018-2029)
  • 1.6.5 Asia-Pacific Cancer Companion Diagnostic Market Size and Prospect (2018-2029)
  • 1.6.6 South America Cancer Companion Diagnostic Market Size and Prospect (2018-2029)
  • 1.6.7 Middle East and Africa Cancer Companion Diagnostic Market Size and Prospect (2018-2029)

2 Company Profiles

• 2.1 AmoyDx
  • 2.1.1 AmoyDx Details
  • 2.1.2 AmoyDx Major Business
  • 2.1.3 AmoyDx Cancer Companion Diagnostic Product and Solutions
  • 2.1.4 AmoyDx Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  • 2.1.5 AmoyDx Recent Developments and Future Plans
• 2.2 Novogene
  • 2.2.1 Novogene Details
  • 2.2.2 Novogene Major Business
  • 2.2.3 Novogene Cancer Companion Diagnostic Product and Solutions
  • 2.2.4 Novogene Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  • 2.2.5 Novogene Recent Developments and Future Plans
• 2.3 Illumina
  • 2.3.1 Illumina Details
  • 2.3.2 Illumina Major Business
  • 2.3.3 Illumina Cancer Companion Diagnostic Product and Solutions
  • 2.3.4 Illumina Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  • 2.3.5 Illumina Recent Developments and Future Plans
• 2.4 Roche
  • 2.4.1 Roche Details
  • 2.4.2 Roche Major Business
  • 2.4.3 Roche Cancer Companion Diagnostic Product and Solutions
  • 2.4.4 Roche Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  • 2.4.5 Roche Recent Developments and Future Plans
• 2.5 Agilent
  • 2.5.1 Agilent Details
  • 2.5.2 Agilent Major Business
  • 2.5.3 Agilent Cancer Companion Diagnostic Product and Solutions
  • 2.5.4 Agilent Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  • 2.5.5 Agilent Recent Developments and Future Plans
• 2.6 Abbott
  • 2.6.1 Abbott Details
  • 2.6.2 Abbott Major Business
  • 2.6.3 Abbott Cancer Companion Diagnostic Product and Solutions
  • 2.6.4 Abbott Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  • 2.6.5 Abbott Recent Developments and Future Plans
• 2.7 Thermo Fisher
  • 2.7.1 Thermo Fisher Details
  • 2.7.2 Thermo Fisher Major Business
  • 2.7.3 Thermo Fisher Cancer Companion Diagnostic Product and Solutions
  • 2.7.4 Thermo Fisher Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  • 2.7.5 Thermo Fisher Recent Developments and Future Plans
• 2.8 Qiagen
  • 2.8.1 Qiagen Details
  • 2.8.2 Qiagen Major Business
  • 2.8.3 Qiagen Cancer Companion Diagnostic Product and Solutions
  • 2.8.4 Qiagen Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  • 2.8.5 Qiagen Recent Developments and Future Plans
• 2.9 Guardant Health
  • 2.9.1 Guardant Health Details
  • 2.9.2 Guardant Health Major Business
  • 2.9.3 Guardant Health Cancer Companion Diagnostic Product and Solutions
  • 2.9.4 Guardant Health Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  • 2.9.5 Guardant Health Recent Developments and Future Plans

3 Market Competition, by Players

• 3.1 Global Cancer Companion Diagnostic Revenue and Share by Players (2018-2023)
• 3.2 Market Share Analysis (2022)
  • 3.2.1 Market Share of Cancer Companion Diagnostic by Company Revenue
  • 3.2.2 Top 3 Cancer Companion Diagnostic Players Market Share in 2022
  • 3.2.3 Top 6 Cancer Companion Diagnostic Players Market Share in 2022
• 3.3 Cancer Companion Diagnostic Market: Overall Company Footprint Analysis
  • 3.3.1 Cancer Companion Diagnostic Market: Region Footprint
  • 3.3.2 Cancer Companion Diagnostic Market: Company Product Type Footprint
  • 3.3.3 Cancer Companion Diagnostic Market: Company Product Application Footprint
• 3.4 New Market Entrants and Barriers to Market Entry
• 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

• 4.1 Global Cancer Companion Diagnostic Consumption Value and Market Share by Type (2018-2023)
• 4.2 Global Cancer Companion Diagnostic Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

• 5.1 Global Cancer Companion Diagnostic Consumption Value Market Share by Application (2018-2023)
• 5.2 Global Cancer Companion Diagnostic Market Forecast by Application (2024-2029)

6 North America

• 6.1 North America Cancer Companion Diagnostic Consumption Value by Type (2018-2029)
• 6.2 North America Cancer Companion Diagnostic Consumption Value by Application (2018-2029)
• 6.3 North America Cancer Companion Diagnostic Market Size by Country
  • 6.3.1 North America Cancer Companion Diagnostic Consumption Value by Country (2018-2029)
  • 6.3.2 United States Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
  • 6.3.3 Canada Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
  • 6.3.4 Mexico Cancer Companion Diagnostic Market Size and Forecast (2018-2029)

7 Europe

• 7.1 Europe Cancer Companion Diagnostic Consumption Value by Type (2018-2029)
• 7.2 Europe Cancer Companion Diagnostic Consumption Value by Application (2018-2029)
• 7.3 Europe Cancer Companion Diagnostic Market Size by Country
  • 7.3.1 Europe Cancer Companion Diagnostic Consumption Value by Country (2018-2029)
  • 7.3.2 Germany Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
  • 7.3.3 France Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
  • 7.3.4 United Kingdom Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
  • 7.3.5 Russia Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
  • 7.3.6 Italy Cancer Companion Diagnostic Market Size and Forecast (2018-2029)

8 Asia-Pacific

• 8.1 Asia-Pacific Cancer Companion Diagnostic Consumption Value by Type (2018-2029)
• 8.2 Asia-Pacific Cancer Companion Diagnostic Consumption Value by Application (2018-2029)
• 8.3 Asia-Pacific Cancer Companion Diagnostic Market Size by Region
  • 8.3.1 Asia-Pacific Cancer Companion Diagnostic Consumption Value by Region (2018-2029)
  • 8.3.2 China Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
  • 8.3.3 Japan Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
  • 8.3.4 South Korea Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
  • 8.3.5 India Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
  • 8.3.6 Southeast Asia Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
  • 8.3.7 Australia Cancer Companion Diagnostic Market Size and Forecast (2018-2029)

9 South America

• 9.1 South America Cancer Companion Diagnostic Consumption Value by Type (2018-2029)
• 9.2 South America Cancer Companion Diagnostic Consumption Value by Application (2018-2029)
• 9.3 South America Cancer Companion Diagnostic Market Size by Country
  • 9.3.1 South America Cancer Companion Diagnostic Consumption Value by Country (2018-2029)
  • 9.3.2 Brazil Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
  • 9.3.3 Argentina Cancer Companion Diagnostic Market Size and Forecast (2018-2029)

10 Middle East & Africa

• 10.1 Middle East & Africa Cancer Companion Diagnostic Consumption Value by Type (2018-2029)
• 10.2 Middle East & Africa Cancer Companion Diagnostic Consumption Value by Application (2018-2029)
• 10.3 Middle East & Africa Cancer Companion Diagnostic Market Size by Country
  • 10.3.1 Middle East & Africa Cancer Companion Diagnostic Consumption Value by Country (2018-2029)
  • 10.3.2 Turkey Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
  • 10.3.3 Saudi Arabia Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
  • 10.3.4 UAE Cancer Companion Diagnostic Market Size and Forecast (2018-2029)

11 Market Dynamics

• 11.1 Cancer Companion Diagnostic Market Drivers
• 11.2 Cancer Companion Diagnostic Market Restraints
• 11.3 Cancer Companion Diagnostic Trends Analysis
• 11.4 Porters Five Forces Analysis
  • 11.4.1 Threat of New Entrants
  • 11.4.2 Bargaining Power of Suppliers
  • 11.4.3 Bargaining Power of Buyers
  • 11.4.4 Threat of Substitutes
  • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

• 12.1 Cancer Companion Diagnostic Industry Chain
• 12.2 Cancer Companion Diagnostic Upstream Analysis
• 12.3 Cancer Companion Diagnostic Midstream Analysis
• 12.4 Cancer Companion Diagnostic Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology
• 14.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Cancer Companion Diagnostic market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.
Companion diagnostic (CD) is an in vitro diagnostic technology that can provide information about a patient's therapeutic response to a specific therapeutic drug, helping to identify patient groups who can benefit from a certain therapeutic product, thereby improving treatment prognosis. and reduce health care costs. Additionally, companion diagnostics can help identify patient populations most likely to respond to therapeutic agents. The companion diagnostics market is still in its early stages.
The number of cancer patients is gradually increasing, drug accessibility is improving, and the research and development of targeted drugs and immunotherapy continue to increase. This is the main trend of drug development in the next ten years.
The Global Info Research report includes an overview of the development of the Cancer Companion Diagnostic industry chain, the market status of Lung Cancer (Polymerase Chain Reaction (PCR), “Next Generation” Sequencing (NGS)), Colorectal Cancer (Polymerase Chain Reaction (PCR), “Next Generation” Sequencing (NGS)), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Cancer Companion Diagnostic.
Regionally, the report analyzes the Cancer Companion Diagnostic markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Cancer Companion Diagnostic market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Cancer Companion Diagnostic market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Cancer Companion Diagnostic industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Polymerase Chain Reaction (PCR), “Next Generation” Sequencing (NGS)).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Cancer Companion Diagnostic market.
Regional Analysis: The report involves examining the Cancer Companion Diagnostic market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Cancer Companion Diagnostic market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Cancer Companion Diagnostic:
Company Analysis: Report covers individual Cancer Companion Diagnostic players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Cancer Companion Diagnostic This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Lung Cancer, Colorectal Cancer).
Technology Analysis: Report covers specific technologies relevant to Cancer Companion Diagnostic. It assesses the current state, advancements, and potential future developments in Cancer Companion Diagnostic areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Cancer Companion Diagnostic market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Cancer Companion Diagnostic market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Polymerase Chain Reaction (PCR)
“Next Generation” Sequencing (NGS)
Fluorescence In Situ Hybridization (FISH)
Immunohistochemistry (IHC)
Market segment by Application
Lung Cancer
Colorectal Cancer
Breast Cancer
Others
Market segment by players, this report covers
AmoyDx
Novogene
Illumina
Roche
Agilent
Abbott
Thermo Fisher
Qiagen
Guardant Health
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Cancer Companion Diagnostic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Cancer Companion Diagnostic, with revenue, gross margin and global market share of Cancer Companion Diagnostic from 2018 to 2023.
Chapter 3, the Cancer Companion Diagnostic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Cancer Companion Diagnostic market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Cancer Companion Diagnostic.
Chapter 13, to describe Cancer Companion Diagnostic research findings and conclusion.